

November 6, 2018

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Intimation of Conference Call for Investors/ Analyst for Q2 FY19

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Tuesday, November 6, 2018 at 4.30 PM IST to discuss financial and operating performance for Q2 FY 19.

You are requested to take note of the above.


Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary & Legal Head



Encl: As above

Q2 FY19 Earnings Conference Call Tuesday, November 6, 2018 at 04:30 pm IST

Gurgaon, November 2, 2018:

Dr. Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q2 FY19 results. DLPL will be represented by (Hony.) Brig. Dr. Arvind Lal - Chairman and Managing Director, Dr. Om Prakash Manchanda - Whole-time Director and CEO, Mr. Ved Goel - CFO. We would also have Mr. Bharath - Chief Operating Officer and Mr. Rajat Kalra - Company Secretary & Head of Investor Relations.

The conference call will be initiated with a brief discussion by the management on the Q2 FY19 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	<ul style="list-style-type: none">• 04:30 pm IST on Tuesday, November 6, 2018
Universal Access	<ul style="list-style-type: none">• Primary – +91 22 6280 1141• Secondary – +91 22 7115 8042
Local Access	<ul style="list-style-type: none">• +91-7045671221 Available all over India.
Conference dial-in International Toll Number	<ul style="list-style-type: none">• USA – 18667462133
	<ul style="list-style-type: none">• UK – 08081011573
	<ul style="list-style-type: none">• Singapore – 8001012045
	<ul style="list-style-type: none">• Hong Kong – 800964448
Replay	<ul style="list-style-type: none">• +91 22 7194 5757 / +91 22 6663 5757• 71837 (passcode)• Valid from November 06, 2018 to November 13, 2018

-ENDS-

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services* includes 1,110 test panels, 2,028 pathology tests and 1,561 radiology and cardiology tests.

As on March 31, 2018 DLPL's has 193 clinical labs (including National Reference Lab at Delhi), 2,153 Patient Service Centers (PSCs) and 5,624 Pick-up Points (PUPs). In FY17 & FY18, DLPL collected and processed approximately 29.3 million samples and 34.7 million samples from approximately 13.3 million and 15.2 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited:

Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com/>

*As on 31st March, 2017

For further information please contact:

Ved Goel / Rajat Kalra
Dr. Lal PathLabs Limited
Tel: +91 124 301 6500
Fax: +91 124 423 4468
E-mail: Ved.Goel@lalpathlabs.com
Rajat.Kalra@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki
CDR India
Tel: +91 22 66451209 / 1221
Fax: +91 22 66451213
Email: siddharth@cdr-india.com
nishid@cdr-india.com